The US Food and Drug Administration (FDA) has approved expanded use of Casgevy (exagamglogene autotemcel) for the treatment of people ages two years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT).
Casgevy, from Vertex, is the first approved genetic therapy indicated for children as young as two years for both SCD and TDT.
Vertex has established a network of independently operated, authorised treatment centres (ATCs) throughout the US to offer Casgevy to eligible patients through existing access and reimbursement pathways.
Today, there are more than 75 activated ATCs in the US.
